- In full:
- Sir Gregory Paul Winter
- Born:
- April 14, 1951, Leicester, England (age 75)
- Founder:
- Cambridge Antibody Technology
- Domantis
- Awards And Honors:
- Nobel Prize (2018)
- Subjects Of Study:
- adalimumab
- antibody
- bacteriophage
- breast cancer
- cancer
- gene
- humanized antibody
Gregory P. Winter
-
Who is Gregory P. Winter?
Gregory P. Winter (born in Leicester, England, on April 14, 1951) is a British biochemist celebrated for his groundbreaking work in developing humanized antibodies and pioneering the application of phage display technology for fully human therapeutic antibodies.
Winter's early research focused on site-directed mutagenesis in antibodies, leading to the creation of humanized antibodies that mitigated dangerous immune reactions in patients. This breakthrough enabled the development of drugs like trastuzumab (Herceptin) for breast cancer and bevacizumab (Avastin) for certain cancers and macular degeneration.
His refinement of phage display technology allowed for the generation of fully human antibody proteins, leading to the creation of adalimumab (Humira), which was approved for rheumatoid arthritis treatment in 2002. Winter is a recipient of the 2018 Nobel Prize in Chemistry and a knighthood.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is a biochemist?
A biochemist studies the chemical and physical principles of substances and processes in living organisms. They apply chemistry to understand life at a molecular level, exploring areas like metabolism, genetics, and the structure of biomolecules. Their work helps in understanding diseases, developing new drugs, and improving food production.
Gregory P. Winter (born in 1951) is a British biochemist known for his work on therapeutic antibodies, particularly the development of humanized antibodies. His work led to new treatments for cancer and autoimmune diseases. Winter shared the 2018 Nobel Prize in Chemistry for his work.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What are Gregory P. Winter's most important scientific discoveries?
Gregory P. Winter is a British biochemist celebrated for his groundbreaking work in developing humanized antibodies and his research into the directed evolution of antibodies. He also refined phage display technology for producing fully human therapeutic antibodies.
Key discoveries and contributions:
- Humanized antibodies Winter engineered humanized antibodies to prevent dangerous immune reactions in patients, leading to drugs like trastuzumab (Herceptin) for breast cancer and bevacizumab (Avastin) for certain cancers and macular degeneration.
- Phage display technology Winter refined this technology to create fully human antibody proteins, resulting in the development of adalimumab (Humira) for rheumatoid arthritis and other inflammatory conditions.
- Directed evolution His work facilitated directed evolution, allowing researchers to create variant antibody proteins with improved binding affinity and selectivity for therapeutic targets.
Winter's work led to the founding of several biotech companies, including Cambridge Antibody Technology, Domantis, and Bicycle Therapeutics. In 2018, he shared the Nobel Prize in Chemistry with George P. Smith and Frances H. Arnold for his work on therapeutic antibodies.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How did Gregory P. Winter change the way medicines can be made?
Gregory P. Winter engineered humanized antibodies to avoid immune reactions in patients, as earlier versions of therapeutic antibodies were derived from mouse proteins. He replaced sections of the mouse antibody that stimulated unwanted immune reactions with human antibody fragments. This facilitated the creation of drugs like trastuzumab (Herceptin) and bevacizumab (Avastin).
Winter also refined phage display technology for producing fully human antibody proteins, which allowed for directed evolution, deriving variant antibody proteins with improved binding affinity and selectivity for therapeutic targets. Adalimumab (Humira) was the first fully human antibody made this way and was approved to treat rheumatoid arthritis in 2002.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What are monoclonal antibodies, and how did Gregory P. Winter help develop them?
Monoclonal antibodies are artificially produced antibodies derived from a single B cell clone, creating a large quantity of identical cells that target the same epitope on a specific antigen, such as a cancer cell.
Gregory P. Winter refined phage display technology for producing human antibody proteins, reducing the risk of adverse immune reactions compared to animal-derived antibodies. This innovation led to the development of fully human antibodies like adalimumab (Humira), used to treat rheumatoid arthritis. Winter's work in this area was so impactful that he shared the 2018 Nobel Prize in Chemistry with George P. Smith and Frances H. Arnold.
4 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
Why did Gregory P. Winter receive the Nobel Prize in Chemistry?
Gregory P. Winter, a British biochemist, shared the 2018 Nobel Prize in Chemistry with George P. Smith and Frances H. Arnold for his work on therapeutic antibodies.
Winter engineered humanized antibodies to avoid dangerous immune reactions in patients, which facilitated the development of drugs like trastuzumab (Herceptin) for breast cancer and bevacizumab (Avastin) for certain cancers and macular degeneration. He also refined phage display technology for generating fully human antibody proteins, leading to adalimumab (Humira), the first fully human antibody produced this way, used to treat rheumatoid arthritis and other inflammatory conditions.
4 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
Gregory P. Winter (born April 14, 1951, Leicester, England) is a British biochemist known for his development of the first humanized antibodies, his research on the directed evolution of antibodies, and his application of phage display technology for the development of fully human therapeutic antibodies. Winter was awarded the 2018 Nobel Prize in Chemistry, shared with American biochemists George P. Smith and Frances H. Arnold, for his scientific breakthroughs relating to the development of therapeutic antibodies.
Winter spent his youth in West Africa, thriving in the warm climate after a sickly infanthood in England. He later returned to England for undergraduate studies at Trinity College, Cambridge, completing a degree in 1973, and in 1976 earned a Ph.D. from the Medical Research Council (MRC) Laboratory of Molecular Biology at Cambridge. In 1981, following postdoctoral fellowships at Imperial College London, and the Institute of Genetics at Cambridge, Winter joined the faculty at the MRC Laboratory of Molecular Biology. He remained there for the duration of his career, eventually serving as its deputy director and, in 2014, being made professor emeritus.
In the early 1980s, after investigating relationships between gene mutation and protein function, Winter focused his research on site-directed mutagenesis in antibodies. At the time, therapeutic antibodies developed for use in humans were derived from mouse proteins, which could cause potentially dangerous immune reactions in human patients. To overcome this problem, Winter engineered so-called humanized antibodies, in which the sections of the mouse antibody that stimulated unwanted immune reactions were replaced by human antibody fragments. The breakthrough facilitated the eventual development of drugs such as trastuzumab (Herceptin), approved for the treatment of breast cancer, and bevacizumab (Avastin), approved for use against certain types of cancer and for age-related macular degeneration.
Winter later refined phage display technology, originally developed by Smith, to allow for the generation of fully human antibody proteins by fusion phages (bacteriophages) produced in the laboratory, circumventing potential limitations associated with his previously developed humanization process. Phage display technology proved critical to the process of directed evolution, whereby researchers are able to derive variant antibody proteins with improved binding affinity and high selectivity for their therapeutic targets using directed mutagenic approaches. The first fully human antibody produced using Winter’s phage display technique to be marketed for use in humans was adalimumab (Humira), which was approved by the U.S. Food and Drug Administration in 2002 for the treatment of rheumatoid arthritis. The drug was later approved for the treatment of inflammatory bowel disease, psoriasis, and certain other inflammatory conditions.
Over the course of Winter’s career, he founded or cofounded several biotech companies to facilitate the development of his novel therapeutic agents. Among them were Cambridge Antibody Technology in 1989, which was later purchased by AstraZeneca; Domantis in 2000, which was acquired by GlaxoSmithKline in 2006; and Bicycle Therapeutics in 2009, which focused on the chemical synthesis and therapeutic development of small compounds known as bicyclic peptides. Winter received numerous awards and honours throughout his career, including the King Faisal International Prize for Medicine (1995) and the Royal Medal (2011). He was a fellow of multiple organizations, including Trinity College and the Royal Society. He received a knighthood for his contributions to molecular biology in 2004, and in 2012 he was made Master of Trinity at Trinity College.